摘要
T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors(TCRs).Cancer immunotherapy,by relying on this basic recognition method,boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells.T cells genetically equipped with chimeric antigen receptors(CARs)or TCRs have shown remarkable effectiveness in treating some hematological malignancies,although the efficacy of engineered T cells in treating solid tumors is far from satisfactory.In this review,we summarize the development of genetically engineered T cells,outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy,and discuss strategies for improving the performance of these T cells in fighting cancers.
基金
This work was supported by the National Key Research and Development Program of China(2016YFC1303403)
the National Natural and Scientific Foundation of China(81572981/H1611 and 81672397/H1617)
the National High-Tech R&D Program(863 Program
2014AA020704)
the Science and Technology Major Project of Sichuan Province of China(2017SZDZX0012).
